k141_138045_14	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.7	529	539	655	1.80e-64	221
k141_138045_14	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.7	529	539	655	2.50e-64	220
k141_138045_14	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.5	529	539	655	2.50e-64	220
k141_138045_14	SARG|gb|AKA86814|ARO:3003746|optrA	26.5	529	539	655	2.50e-64	220
k141_138045_14	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.8	529	539	655	3.47e-64	220
k141_138045_14	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.5	529	539	655	6.69e-64	219
k141_138045_14	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.5	529	539	655	6.69e-64	219
k141_138045_14	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.5	529	539	655	6.69e-64	219
k141_138045_14	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.5	529	539	655	6.69e-64	219
k141_138045_14	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.5	529	539	655	9.29e-64	219
k141_138045_35	SARG|AAG21695	30.5	105	211	214	1.98e-06	45.8
k141_138045_35	SARG|AF139725.gene.p01	32.1	78	211	214	6.69e-06	44.3
k141_138045_35	SARG|AAF24171	32.1	78	211	214	6.69e-06	44.3
k141_138045_35	NCBI|WP_063856932.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	32.1	78	211	214	6.69e-06	44.3
k141_138045_35	NCBI|WP_063856933.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	32.1	78	211	214	6.69e-06	44.3
k141_138045_35	NCBI|WP_063856934.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	32.1	78	211	214	6.69e-06	44.3
k141_138045_35	SARG|AAK91782	32.1	78	211	214	6.69e-06	44.3
k141_138045_49	NCBI|BAB64566.1|1|1|bexA|bexA|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_BexA|AMR|efflux	24.3	309	470	443	2.09e-13	70.9
k141_32236_3	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	23.2	185	252	229	9.98e-07	47.4
k141_32236_13	SARG|gi|545266912|ref|WP_021557970.1|	28.0	322	323	660	8.67e-33	127
k141_32236_13	SARG|gi|851965596|ref|WP_048234849.1|	29.2	240	323	660	1.18e-32	126
k141_32236_13	SARG|gi|851899656|ref|WP_048211088.1|	28.8	240	323	660	1.18e-32	126
k141_32236_13	SARG|YP_002850217	29.2	240	323	660	1.61e-32	126
k141_32236_13	SARG|gi|353570208|gb|EHC34541.1|	29.3	242	323	660	1.61e-32	126
k141_32236_13	SARG|gi|489931383|ref|WP_003834702.1|	29.6	240	323	660	1.61e-32	126
k141_32236_13	SARG|gi|486404556|ref|WP_001607766.1|	27.6	322	323	660	2.19e-32	125
k141_32236_13	SARG|gi|851928593|ref|WP_048220996.1|	27.0	282	323	660	2.19e-32	125
k141_32236_13	SARG|gi|696369048|ref|WP_032944060.1|	29.2	240	323	660	2.19e-32	125
k141_32236_13	SARG|gi|757799830|ref|WP_043017032.1|	30.8	240	323	660	2.19e-32	125
k141_32236_59	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.3	150	1355	219	3.13e-21	92.8
k141_32236_59	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	34.7	121	1355	231	4.55e-18	84.0
k141_32236_59	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	34.2	120	1355	252	1.71e-17	82.8
k141_32236_59	CARD|gb|AEX49906.1|ARO:3003583|basS	28.3	212	1355	477	1.17e-16	83.6
k141_32236_59	CARD|gb|AAD51348.1|ARO:3003066|smeR	33.3	120	1355	229	1.03e-15	77.0
k141_32236_59	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	26.9	212	1355	341	7.57e-11	64.3
k141_32236_59	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	30.9	123	1355	233	1.12e-09	59.3
k141_175771_15	SARG|ZP_04606269	25.0	240	247	299	1.08e-13	68.2
k141_180861_16	CARD|gb|ATC67679.1|ARO:3000838|arlR	39.1	220	231	219	3.42e-48	157
k141_180861_16	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	33.9	218	231	228	1.38e-40	137
k141_180861_16	CARD|gb|AAG06465.1|ARO:3005063|cprR	34.7	216	231	223	4.79e-40	136
k141_180861_16	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.3	225	231	231	5.37e-34	120
k141_180861_16	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	32.8	229	231	235	1.65e-33	119
k141_180861_16	CARD|gb|AAD51348.1|ARO:3003066|smeR	33.2	223	231	229	2.82e-33	119
k141_180861_16	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	32.9	225	231	231	4.17e-33	118
k141_180861_16	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.9	225	231	231	4.17e-33	118
k141_180861_16	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.9	225	231	231	4.17e-33	118
k141_180861_16	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.3	226	231	231	8.24e-33	117
k141_180861_19	NCBI|AAN29241.1|1|1|bepE|bepE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepE|AMR|efflux	22.2	1042	1033	1051	5.22e-56	210
k141_180861_19	SARG|YP_348488	23.6	1054	1033	1043	1.19e-55	209
k141_180861_19	SARG|YP_001186705	23.3	1019	1033	1017	1.88e-55	208
k141_180861_19	SARG|gi|496339859|ref|WP_009049037.1|	23.4	1055	1033	1043	2.81e-55	207
k141_180861_19	SARG|gi|852273548|ref|WP_048328542.1|	24.2	1053	1033	1043	4.98e-55	207
k141_180861_19	ResF|tmexD4_1_CP091084_1	24.9	1050	1033	1044	6.65e-55	206
k141_180861_19	SARG|gi|487969243|ref|WP_002042236.1|	23.3	1060	1033	1031	2.62e-54	204
k141_180861_19	SARG|gi|565648659|ref|WP_023896298.1|	23.3	1060	1033	1031	4.64e-54	204
k141_180861_19	SARG|YP_001668663	23.8	1057	1033	1043	4.88e-54	204
k141_180861_19	SARG|NC_011595.7057907.p01	23.3	1060	1033	1031	6.18e-54	203
k141_180861_61	SARG|P07287	33.0	185	266	381	1.66e-19	85.9
k141_180861_61	megares|MEG_2827|Drugs|MLS|23S_rRNA_methyltransferases|ERME_1	33.0	185	266	381	1.66e-19	85.9
k141_180861_61	SARG|P45438	31.6	190	266	287	7.62e-18	80.1
k141_180861_61	SARG|Q04720	31.1	190	266	287	5.14e-17	77.8
k141_180861_61	SARG|M29832.gene.p01	31.1	190	266	287	5.14e-17	77.8
k141_180861_61	SARG|1112175A	32.3	186	266	370	2.58e-14	70.9
k141_180861_76	CARD|gb|AAC75429.1|ARO:3000833|evgS	33.6	250	829	1197	4.14e-31	130
k141_180861_76	CARD|gb|AAD51347.1|ARO:3003067|smeS	29.5	224	829	467	3.16e-17	84.3
k141_180861_76	CARD|gb|ABD30512.1|ARO:3000839|arlS	27.7	213	829	451	4.96e-16	80.5
k141_180861_95	SARG|gb|ABA71733.1|ARO:3002972|vanTG	33.7	368	844	712	2.67e-51	191
k141_180861_95	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	33.9	369	844	712	4.93e-43	166
k141_180861_95	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	31.7	366	844	711	1.57e-42	164
k141_180861_95	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	30.8	364	844	700	8.78e-37	147
k141_180861_95	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	30.7	368	844	706	1.20e-35	143
k141_180861_95	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	29.1	364	844	700	2.72e-35	142
k141_180861_95	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	25.7	486	844	451	3.81e-35	138
k141_180861_95	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	29.1	368	844	366	9.22e-35	135
k141_180861_95	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	26.0	493	844	481	1.46e-34	137
k141_180861_95	SARG|gi|498467693|ref|WP_010773049.1|	28.8	365	844	700	1.51e-34	140
k141_180861_110	CARD|gb|AAC75429.1|ARO:3000833|evgS	29.1	392	1472	1197	1.86e-32	136
k141_180861_110	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.7	119	1472	219	7.12e-18	83.2
k141_180861_110	CARD|gb|AAD51348.1|ARO:3003066|smeR	34.7	118	1472	229	3.37e-16	78.6
k141_180861_110	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	33.3	123	1472	230	2.38e-14	73.2
k141_180861_110	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.5	123	1472	231	2.42e-14	73.2
k141_180861_110	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	31.7	123	1472	231	2.42e-14	73.2
k141_180861_110	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	31.7	123	1472	231	4.43e-14	72.4
k141_180861_110	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	20.8	207	1472	359	9.68e-13	70.5
k141_180861_110	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	31.2	141	1472	232	2.26e-12	67.4
k141_180861_110	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	31.9	141	1472	232	2.26e-12	67.4
k141_180861_112	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.3	119	1502	219	7.48e-20	89.0
k141_180861_112	CARD|gb|AAD51348.1|ARO:3003066|smeR	37.2	121	1502	229	7.55e-17	80.5
k141_180861_112	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	23.9	213	1502	359	7.21e-16	80.1
k141_180861_112	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	24.4	217	1502	357	2.26e-15	78.6
k141_180861_112	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	24.4	217	1502	357	2.26e-15	78.6
k141_180861_112	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	22.8	206	1502	364	5.62e-11	65.1
k141_180861_112	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	22.8	206	1502	364	5.62e-11	65.1
k141_180861_138	SARG|AAN28721	67.6	74	400	108	2.43e-31	114
k141_180861_143	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	26.9	234	514	365	5.46e-14	72.4
k141_180861_143	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	25.2	234	514	370	2.39e-12	67.4
k141_180861_143	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	23.8	227	514	341	6.37e-12	65.9
k141_180861_144	CARD|gb|ATC67679.1|ARO:3000838|arlR	34.2	222	234	219	1.10e-34	122
k141_180861_144	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	222	234	219	6.09e-34	120
k141_180861_144	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	222	234	219	8.57e-34	120
k141_180861_144	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	222	234	220	8.80e-34	120
k141_180861_144	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	222	234	220	1.24e-33	119
k141_180861_144	CARD|gb|ADM92605.1|ARO:3000553|adeR	28.1	228	234	247	4.81e-28	105
k141_180861_144	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	28.6	224	234	233	4.95e-28	105
k141_180861_144	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	28.1	224	234	231	1.30e-27	104
k141_180861_144	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	26.7	221	234	223	6.63e-25	97.1
k141_11744_8	SARG|gi|445996710|ref|WP_000074565.1|	38.6	176	214	309	1.25e-34	124
k141_11744_8	SARG|gi|445996719|ref|WP_000074574.1|	38.1	176	214	309	9.55e-34	121
k141_11744_8	SARG|gi|488120365|ref|WP_002191762.1|	38.1	176	214	309	1.34e-33	121
k141_11744_8	SARG|gi|507044560|ref|WP_016115614.1|	38.7	168	214	306	2.48e-33	120
k141_11744_8	SARG|gi|488068784|ref|WP_002140181.1|	37.5	176	214	309	2.63e-33	120
k141_11744_8	SARG|gi|488067981|ref|WP_002139378.1|	37.5	176	214	309	3.69e-33	120
k141_11744_8	SARG|gi|487936534|ref|WP_002010000.1|	37.5	176	214	309	3.69e-33	120
k141_11744_8	SARG|gi|447057510|ref|WP_001134766.1|	37.5	176	214	309	3.69e-33	120
k141_11744_8	SARG|gi|445996723|ref|WP_000074578.1|	37.8	172	214	309	5.17e-33	119
k141_11744_8	SARG|gi|445996722|ref|WP_000074577.1|	37.8	172	214	309	5.17e-33	119
k141_90702_31	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	36.9	1094	1163	1033	4.81e-239	708
k141_90702_31	SARG|gb|AEY83581|ARO:3000510|mupB	36.9	1094	1163	1033	4.81e-239	708
k141_90702_31	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	34.8	1145	1163	1024	4.04e-238	705
k141_90702_31	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	34.8	1145	1163	1024	4.04e-238	705
k141_90702_31	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	34.7	1145	1163	1024	4.97e-236	700
k141_90702_31	SARG|gb|CAA53189|ARO:3000521|mupA	34.7	1145	1163	1024	4.97e-236	700
k141_90702_31	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	34.5	1180	1163	1107	8.54e-213	642
k141_90702_31	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	34.5	1180	1163	1107	8.54e-213	642
k141_90702_41	SARG|gb|WP_001572373.1|ARO:3004684|MCR-9	26.8	503	569	539	9.87e-31	125
k141_90702_41	NCBI|QKF95689.1|1|1|mcr-9.3|mcr-9||1|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-9.3|AMR|peptide	26.8	503	569	539	9.87e-31	125
k141_90702_41	NCBI|MBO4175406.1|1|1|mcr-9.2|mcr-9||1|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-9.2|AMR|peptide	26.8	503	569	540	9.95e-31	125
k141_90702_41	SARG|WP_065804663.1	29.3	481	569	541	1.00e-30	125
k141_90702_41	SARG|gb|AUN87920.1|ARO:3004500|MCR-3.11	29.3	481	569	541	1.00e-30	125
k141_90702_41	NCBI|WP_136512112.1|1|1|mcr-3.29|mcr-3||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-3.29|AMR|peptide	29.3	481	569	541	1.00e-30	125
k141_90702_41	NCBI|WP_039039919.1|1|1|mcr-3.38|mcr-3||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-3.38|AMR|peptide	28.3	501	569	540	1.34e-30	124
k141_90702_41	NCBI|WP_111273845.1|1|1|mcr-3.16|mcr-3||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-3.16|AMR|peptide	29.6	507	569	540	2.43e-30	124
k141_90702_41	NCBI|WP_111273847.1|1|1|mcr-3.18|mcr-3||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-3.18|AMR|peptide	29.6	507	569	540	2.43e-30	124
k141_90702_41	NCBI|WP_150823496.1|1|1|mcr-3.28|mcr-3||2|COLISTIN|COLISTIN|phosphoethanolamine--lipid_A_transferase_MCR-3.28|AMR|peptide	29.1	481	569	541	2.45e-30	124
k141_118064_14	SARG|gb|AAC75089.1|ARO:3003577|ugd	27.0	359	438	388	6.28e-39	143
k141_118064_35	SARG|gb|WP_104671188.1|ARO:3003948|efrA	27.0	215	207	575	1.12e-14	70.9
k141_118064_35	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	24.2	223	207	655	6.01e-13	65.9
k141_118064_35	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	24.2	223	207	655	8.14e-13	65.5
k141_118064_35	SARG|gb|AKA86814|ARO:3003746|optrA	24.2	223	207	655	8.14e-13	65.5
k141_118064_35	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	24.7	223	207	655	9.17e-12	62.4
k141_118064_35	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.8	223	207	655	1.24e-11	62.0
k141_118064_35	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.8	223	207	655	1.24e-11	62.0
k141_118064_35	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.8	223	207	655	1.68e-11	61.6
k141_118064_35	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.8	223	207	655	1.68e-11	61.6
k141_118064_35	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	23.8	223	207	655	1.68e-11	61.6
k141_118064_40	SARG|EU408352.1.gene1.p01	32.9	419	480	469	6.81e-65	216
k141_118064_40	SARG|YP_371057	33.4	422	480	511	8.18e-59	201
k141_118064_40	SARG|gb|BAE06009.1|ARO:3003700|opmE	29.8	420	480	491	1.64e-51	181
k141_118064_40	NCBI|AAQ92182.1|1|1|emhC|emhC||1|EFFLUX|EFFLUX|efflux_RND_transporter_outer_membrane_subunit_EmhC|AMR|efflux	30.2	414	480	486	2.89e-50	177
k141_118064_40	SARG|gb|BAM10414.1|ARO:3003039|oprA	26.8	474	480	467	1.99e-49	174
k141_118064_40	SARG|NC_008702.1.4607681.p01	29.9	431	480	469	4.00e-49	174
k141_118064_40	NCBI|AAD15665.1|1|1|tbtM|tbtM||1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_outer_membrane_channel_subunit_TbtM|AMR|efflux	29.7	414	480	476	3.28e-48	171
k141_118064_40	SARG|NC_008702.1.4606278.p01	27.9	416	480	467	3.84e-48	171
k141_118064_40	SARG|YP_788911	27.9	419	480	487	2.81e-46	166
k141_118064_40	SARG|gb|AAG07595.1|ARO:3000809|opmD	27.7	419	480	487	1.98e-45	164
k141_118064_41	SARG|gb|BAE06007.1|ARO:3003698|mexP	34.6	361	366	385	1.32e-48	167
k141_118064_41	NCBI|WP_047693838.1|1|1|oqxA6|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA6|AMR|multidrug	32.2	363	366	391	1.14e-47	165
k141_118064_41	NCBI|WP_063865358.1|1|1|oqxA2|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA2|AMR|multidrug	32.5	363	366	391	2.23e-47	164
k141_118064_41	NCBI|WP_063865399.1|1|1|oqxA9|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA9|AMR|multidrug	32.5	363	366	391	2.23e-47	164
k141_118064_41	SARG|gb|AAP43109.1|ARO:3003922|oqxA	32.2	363	366	391	3.11e-47	164
k141_118064_41	NCBI|WP_063865373.1|1|1|oqxA5|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA5|AMR|multidrug	32.2	363	366	391	3.11e-47	164
k141_118064_41	NCBI|WP_063865390.1|1|1|oqxA8|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA8|AMR|multidrug	32.8	363	366	391	3.11e-47	164
k141_118064_41	NCBI|WP_004212918.1|1|1|oqxA11|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA11|AMR|multidrug	32.2	363	366	391	4.35e-47	163
k141_118064_41	NCBI|WP_063865368.1|1|1|oqxA4|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA4|AMR|multidrug	32.2	363	366	391	4.35e-47	163
k141_118064_41	NCBI|WP_004890321.1|1|1|oqxA3|oqxA|efflux|2|PHENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_OqxA3|AMR|multidrug	32.2	363	366	391	4.35e-47	163
k141_118064_42	SARG|gi|950554518|ref|WP_057427257.1|	45.6	1034	1040	1060	1.11e-294	847
k141_118064_42	SARG|YP_236040	45.2	1043	1040	1063	4.45e-292	841
k141_118064_42	SARG|gi|504104202|ref|WP_014338188.1|	45.4	1043	1040	1059	7.82e-292	840
k141_118064_42	SARG|gi|489294780|ref|WP_003202298.1|	45.3	1043	1040	1059	7.82e-292	840
k141_118064_42	SARG|gi|950580033|ref|WP_057445338.1|	45.1	1043	1040	1063	8.91e-292	840
k141_118064_42	SARG|gi|489512421|ref|WP_003417270.1|	45.1	1043	1040	1063	8.91e-292	840
k141_118064_42	SARG|gi|514421161|ref|WP_016568324.1|	45.1	1043	1040	1063	1.26e-291	840
k141_118064_42	SARG|gi|490552377|ref|WP_004417486.1|	45.1	1043	1040	1063	1.78e-291	839
k141_118064_42	SARG|gi|639494054|ref|WP_024665043.1|	45.1	1043	1040	1063	1.78e-291	839
k141_118064_42	SARG|gi|808074169|ref|WP_046235276.1|	45.1	1043	1040	1063	2.52e-291	839
k141_48937_6	SARG|DQ018711.1.gene4.p01	27.2	195	307	322	3.52e-16	76.6
k141_48937_6	SARG|gi|737310392|ref|WP_035293250.1|	26.7	195	307	323	1.03e-14	72.4
k141_48937_6	SARG|gi|738848198|ref|WP_036737307.1|	28.7	195	307	323	2.13e-13	68.6
k141_48937_21	CARD|gb|AAC75429.1|ARO:3000833|evgS	32.4	417	906	1197	4.01e-45	175
k141_48937_21	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.0	122	906	228	1.77e-14	72.8
k141_48937_21	CARD|gb|ATC67679.1|ARO:3000838|arlR	31.0	116	906	219	5.23e-11	62.4
k141_48937_21	CARD|gb|ADM92605.1|ARO:3000553|adeR	31.2	125	906	247	1.06e-10	62.0
k141_48937_21	CARD|gb|AAD51348.1|ARO:3003066|smeR	29.4	102	906	229	2.20e-09	57.8
k141_48937_21	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	32.7	101	906	225	5.09e-09	56.6
k141_48937_21	CARD|gb|AAC73788.1|ARO:3003841|kdpE	32.7	101	906	225	5.09e-09	56.6
k141_48937_30	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	31.3	259	319	323	1.37e-24	100
k141_48937_30	SARG|AAD51059	30.5	256	319	323	9.42e-24	98.2
k141_48937_30	SARG|AAR37059	30.1	256	319	323	3.40e-23	96.7
k141_48937_30	SARG|AAD41881	30.1	256	319	323	3.40e-23	96.7
k141_48937_30	SARG|gi|740152780|ref|WP_037997109.1|	30.4	240	319	322	3.14e-22	94.0
k141_48937_30	SARG|AAD42183	30.5	256	319	322	4.32e-22	93.6
k141_48937_37	SARG|gb|APB03219.1|ARO:3003986|TaeA	43.3	506	566	648	4.46e-124	378
k141_48937_37	SARG|M80346.gene.p01	34.0	527	566	551	6.40e-63	215
k141_48937_37	megares|MEG_1491|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|CARA_1	34.0	527	566	551	6.40e-63	215
k141_48937_37	SARG|X63451.gene.p01	32.6	518	566	550	1.22e-57	201
k141_48937_37	megares|MEG_6558|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|SRMB_1	32.6	518	566	550	1.22e-57	201
k141_48937_37	SARG|gb|NP_388442.1|ARO:3004476|vmlR	29.9	528	566	547	4.02e-54	191
k141_48937_37	SARG|gi|488321355|ref|WP_002390740.1|	28.3	554	566	492	9.82e-41	153
k141_48937_37	SARG|AY004350.gene.p01	28.3	554	566	492	1.22e-39	150
k141_48937_37	SARG|gi|488216250|ref|WP_002287458.1|	28.2	554	566	492	8.01e-39	147
k141_48937_37	SARG|gi|488231473|ref|WP_002302681.1|	28.2	554	566	492	1.10e-38	147
k141_107502_7	SARG|gb|WP_122630831.1|ARO:3006864|CRD3-1	40.3	62	269	303	9.41e-06	45.1
k141_191862_22	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.8	103	1364	232	5.31e-17	80.9
k141_191862_22	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.8	103	1364	232	5.31e-17	80.9
k141_191862_22	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.5	109	1364	219	1.37e-16	79.3
k141_191862_22	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.9	103	1364	231	1.64e-14	73.6
k141_191862_34	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.2	117	1362	219	4.19e-19	86.7
k141_191862_34	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.2	119	1362	232	5.30e-17	80.9
k141_191862_34	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	41.2	119	1362	232	5.30e-17	80.9
k141_191862_34	CARD|gb|AAD51348.1|ARO:3003066|smeR	36.4	121	1362	229	1.90e-15	76.3
k141_191862_34	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	39.4	104	1362	239	8.53e-14	71.6
k141_191862_34	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.1	105	1362	231	3.35e-13	69.7
k141_191862_34	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	33.1	139	1362	341	2.28e-08	56.6
k141_191862_61	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.4	851	895	1024	2.24e-46	179
k141_191862_61	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	22.5	835	895	1024	3.94e-46	178
k141_191862_61	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	22.4	851	895	1024	5.24e-46	177
k141_191862_61	SARG|gb|CAA53189|ARO:3000521|mupA	22.5	835	895	1024	9.23e-46	177
k141_191862_73	SARG|gb|AGZ55247.1|ARO:3002814|clbA	30.4	332	346	349	7.30e-41	145
k141_191862_73	SARG|gb|BAD63613.1|ARO:3002816|clbC	32.2	335	346	350	6.05e-37	135
k141_191862_76	CARD|gb|AAK37618.1|ARO:3005008|TxR	42.9	231	418	318	2.84e-61	200
k141_191862_91	SARG|gi|738114161|ref|WP_036072414.1|	24.2	194	388	469	8.68e-07	49.7
k141_191862_93	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.3	215	913	381	8.83e-23	100
k141_191862_93	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.3	215	913	381	8.83e-23	100
k141_191862_93	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.8	215	913	381	6.95e-22	97.8
k141_191862_93	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.8	215	913	381	6.95e-22	97.8
k141_191862_93	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	29.1	220	913	367	1.16e-19	90.9
k141_191862_93	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	29.1	220	913	368	1.18e-19	90.9
k141_191862_93	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	29.6	216	913	382	1.96e-17	84.3
k141_191862_93	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	29.6	216	913	382	1.96e-17	84.3
k141_191862_93	CARD|gb|ATC67679.1|ARO:3000838|arlR	33.1	121	913	219	4.71e-17	80.1
k141_191862_93	CARD|gb|AAG06465.1|ARO:3005063|cprR	40.5	116	913	223	7.87e-16	76.6
k141_191862_101	SARG|gi|1035706844|ref|WP_064548272.1|	28.7	174	937	648	2.31e-09	60.1
k141_191862_101	SARG|gi|671541568|ref|WP_031525212.1|	31.8	107	937	648	2.44e-07	53.5
k141_191862_105	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	38.7	106	1351	228	7.82e-18	83.2
k141_191862_105	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.9	126	1351	219	2.19e-17	81.6
k141_191862_105	CARD|gb|AAG05188.1|ARO:3005068|ParR	29.3	123	1351	235	1.29e-14	73.9
k141_191862_105	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	39.6	106	1351	235	3.19e-14	72.8
k141_191862_105	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	40.6	106	1351	232	7.49e-14	71.6
k141_191862_105	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	40.6	106	1351	232	7.49e-14	71.6
k141_191862_105	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	40.6	106	1351	232	7.49e-14	71.6
k141_191862_105	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	40.6	106	1351	232	7.49e-14	71.6
k141_191862_105	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	39.6	106	1351	232	1.85e-13	70.5
k141_191862_105	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	37.7	106	1351	233	4.64e-13	69.3
k141_191862_112	SARG|AAV80410	28.2	458	524	651	8.27e-42	157
k141_191862_112	SARG|L42544.gene.p01	27.9	458	524	651	3.89e-41	155
k141_191862_112	SARG|FN594949.1.gene24.p01	29.1	467	524	640	3.62e-39	150
k141_191862_112	SARG|NP_348076	28.0	464	524	652	5.40e-39	149
k141_191862_112	SARG|gi|164612278|gb|ABY63608.1|	27.2	463	524	639	3.08e-38	147
k141_191862_112	SARG|gi|672386269|gb|AIJ27535.1|	27.8	471	524	639	3.08e-38	147
k141_191862_112	SARG|ABB70049	27.2	463	524	639	3.08e-38	147
k141_191862_112	SARG|ABP89888	27.2	463	524	644	3.20e-38	147
k141_191862_112	SARG|AJ514254.gene.p01	27.8	453	524	640	4.21e-38	147
k141_191862_112	NCBI|WP_003454408.1|1|1|tet(44)|tet(44)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(44)|AMR|tetracycline	28.9	460	524	640	5.72e-38	146
k141_191862_121	SARG|gb|AAG07064.1|ARO:3003693|mexK	28.5	1020	1011	1025	2.06e-132	424
k141_191862_121	CARD|gb|AAG03548.1|ARO:3003681|TriC	26.7	1008	1011	1015	3.86e-122	397
k141_191862_121	SARG|YP_838977	22.2	1066	1011	1061	2.20e-49	189
k141_191862_121	SARG|YP_371056	22.0	1066	1011	1066	2.22e-49	189
k141_191862_121	SARG|CAR56416	22.0	1066	1011	1066	9.09e-49	187
k141_191862_121	SARG|YP_001116031	22.3	1065	1011	1066	1.20e-48	187
k141_191862_121	SARG|ZP_02889083	22.4	1065	1011	1071	1.22e-48	187
k141_191862_121	SARG|YP_001811890	22.4	1065	1011	1066	1.59e-48	186
k141_191862_121	SARG|YP_776582	22.4	1065	1011	1071	2.14e-48	186
k141_191862_121	SARG|YP_002095804	22.3	1021	1011	1066	2.00e-47	183
k141_191862_122	SARG|gb|AAG07065.1|ARO:3003692|mexJ	25.9	355	348	367	1.40e-20	90.5
k141_191862_122	SARG|gi|970301657|ref|WP_058672678.1|	26.0	323	348	371	7.74e-12	64.7
k141_191862_122	SARG|gi|1036665709|ref|WP_064719478.1|	25.2	341	348	369	1.84e-11	63.5
k141_191862_122	SARG|gi|487660603|ref|WP_001751145.1|	23.9	327	348	371	3.32e-11	62.8
k141_191862_122	SARG|gi|983379772|ref|WP_060557066.1|	25.2	326	348	369	5.90e-11	62.0
k141_191862_122	SARG|gi|739066754|ref|WP_036938162.1|	25.2	322	348	369	1.41e-10	60.8
k141_191862_122	SARG|gi|501336065|ref|WP_012367700.1|	25.2	326	348	369	1.88e-10	60.5
k141_191862_122	SARG|gi|857587769|emb|CRL59467.1|	26.3	323	348	369	1.88e-10	60.5
k141_191862_122	SARG|gi|896239619|ref|WP_049236948.1|	25.2	326	348	369	2.52e-10	60.1
k141_191862_122	SARG|gi|810389049|ref|WP_046335163.1|	25.2	326	348	369	2.52e-10	60.1
k141_191862_150	CARD|gb|AAC75429.1|ARO:3000833|evgS	29.9	395	1451	1197	3.05e-34	142
k141_191862_150	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.4	136	1451	219	2.15e-22	96.3
k141_191862_150	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	37.7	122	1451	225	1.12e-19	88.6
k141_191862_150	CARD|gb|AAC73788.1|ARO:3003841|kdpE	37.7	122	1451	225	1.12e-19	88.6
k141_191862_150	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	31.3	166	1451	230	1.62e-17	82.4
k141_191862_150	CARD|gb|AEX49906.1|ARO:3003583|basS	29.7	239	1451	477	2.35e-17	85.9
k141_191862_150	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.1	132	1451	220	7.32e-13	68.6
k141_191862_150	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	23.5	230	1451	359	9.52e-13	70.5
k141_191862_150	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.1	132	1451	219	1.32e-12	67.8
k141_191862_150	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	31.1	132	1451	219	1.32e-12	67.8
k141_191862_158	CARD|gb|AAC75429.1|ARO:3000833|evgS	27.0	381	1311	1197	5.62e-25	112
k141_191862_158	CARD|gb|ADM92605.1|ARO:3000553|adeR	27.3	183	1311	247	3.43e-15	75.9
k141_191862_158	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.5	123	1311	232	4.78e-15	75.1
k141_191862_158	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	32.2	121	1311	231	2.87e-14	72.8
k141_191862_158	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	32.5	117	1311	235	3.09e-14	72.8
k141_191862_158	CARD|gb|AAG06465.1|ARO:3005063|cprR	35.2	108	1311	223	3.77e-13	69.3
k141_191862_158	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	34.9	83	1311	341	2.00e-06	50.4
k141_191862_171	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	24.6	211	524	307	3.64e-13	69.3
k141_191862_171	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	27.9	229	524	574	1.44e-12	68.9
k141_191862_171	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	26.1	207	524	524	2.67e-06	48.9
k141_191862_211	SARG|CAD57199	26.8	209	234	213	5.89e-23	91.7
k141_191862_220	CARD|gb|AAK37618.1|ARO:3005008|TxR	38.9	311	453	318	8.46e-63	205
k141_191862_220	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	26.8	123	453	225	3.49e-06	47.0
k141_191862_220	CARD|gb|AAC73788.1|ARO:3003841|kdpE	26.8	123	453	225	3.49e-06	47.0
k141_191862_220	CARD|gb|AAG06465.1|ARO:3005063|cprR	25.2	115	453	223	8.29e-06	45.8
k141_235035_20	SARG|gi|515990697|ref|WP_017421280.1|	22.3	314	453	442	1.10e-06	49.7
k141_235035_21	SARG|gb|AAG07064.1|ARO:3003693|mexK	29.3	1053	1043	1025	2.47e-140	446
k141_235035_21	CARD|gb|AAG03548.1|ARO:3003681|TriC	28.5	1049	1043	1015	9.40e-132	423
k141_235035_21	CARD|gb|AAG07594.1|ARO:3000808|MexI	23.3	1052	1043	1029	4.40e-51	194
k141_235035_21	NCBI|AAN33534.1|1|1|bepG|bepG|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepG|AMR|efflux	22.3	1080	1043	1074	9.98e-48	184
k141_235035_21	SARG|YP_348488	23.7	1070	1043	1043	3.74e-47	182
k141_235035_21	SARG|gi|852273548|ref|WP_048328542.1|	23.5	1098	1043	1043	2.01e-46	180
k141_235035_21	SARG|gi|685890627|ref|WP_031631929.1|	22.8	1061	1043	1043	3.51e-46	179
k141_235035_21	SARG|YP_838977	22.1	1111	1043	1061	3.67e-46	179
k141_235035_21	SARG|gi|489226605|ref|WP_003134989.1|	22.7	1061	1043	1043	6.14e-46	178
k141_235035_21	SARG|gi|757680562|ref|WP_042911120.1|	22.6	1061	1043	1043	8.13e-46	178
k141_235035_22	SARG|gb|AAG07065.1|ARO:3003692|mexJ	28.3	368	356	367	9.24e-29	113
k141_235035_22	CARD|gb|AAC75135.2|ARO:3000792|mdtA	23.1	325	356	415	7.17e-10	58.9
k141_235035_26	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	38.8	227	500	343	5.43e-46	162
k141_235035_26	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	35.2	227	500	325	6.87e-41	148
k141_235035_26	SARG|gb|AAA26793|ARO:3003748|oleC	35.6	225	500	325	1.32e-40	147
k141_235035_26	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	36.4	217	500	293	1.53e-36	135
k141_235035_26	SARG|gi|507055561|ref|WP_016126482.1|	35.8	212	500	309	1.93e-33	127
k141_235035_26	SARG|gi|446110087|ref|WP_000187942.1|	34.9	218	500	309	5.05e-33	126
k141_235035_26	SARG|gi|488042066|ref|WP_002113463.1|	35.4	212	500	309	5.05e-33	126
k141_235035_26	SARG|gi|488068784|ref|WP_002140181.1|	34.9	212	500	309	6.95e-33	126
k141_235035_26	SARG|gi|895736250|emb|COF64653.1|	35.4	212	500	309	9.58e-33	125
k141_235035_26	SARG|gi|488053456|ref|WP_002124853.1|	34.9	212	500	309	9.58e-33	125
k141_144387_24	SARG|gi|823326845|ref|WP_047080664.1|	44.3	219	228	648	2.08e-58	194
k141_144387_24	SARG|gi|823302270|ref|WP_047057473.1|	44.3	219	228	648	4.04e-58	193
k141_144387_24	SARG|gi|976146774|ref|WP_059305359.1|	44.3	219	228	648	4.04e-58	193
k141_144387_24	SARG|gi|1022664304|ref|WP_063420886.1|	44.3	219	228	648	4.04e-58	193
k141_144387_24	SARG|gi|823309640|ref|WP_047064288.1|	44.3	219	228	648	4.04e-58	193
k141_144387_24	SARG|gi|505807117|ref|WP_015704872.1|	44.3	219	228	648	4.04e-58	193
k141_144387_24	SARG|gi|518923394|ref|WP_020079269.1|	44.3	219	228	648	4.04e-58	193
k141_144387_24	SARG|gi|695797094|ref|WP_032711285.1|	44.3	219	228	648	4.04e-58	193
k141_144387_24	SARG|gi|823299155|ref|WP_047054544.1|	44.3	219	228	648	4.04e-58	193
k141_144387_24	SARG|gi|695793471|ref|WP_032707680.1|	44.3	219	228	648	5.63e-58	192
k141_144387_25	SARG|gi|487135741|ref|WP_001627648.1|	26.1	433	451	451	7.86e-46	164
k141_161196_9	CARD|gb|AAC75136.1|ARO:3000793|mdtB	28.9	1050	1047	1040	1.95e-125	407
k141_161196_9	SARG|YP_001186705	28.6	1036	1047	1017	3.30e-120	392
k141_161196_9	SARG|YP_350221	28.2	1045	1047	1009	1.04e-117	385
k141_161196_9	SARG|gb|BAE06006.1|ARO:3003705|mexN	29.1	1032	1047	1036	4.61e-114	376
k141_161196_9	SARG|CAY51926	28.1	1033	1047	1008	9.81e-114	375
k141_161196_9	SARG|YP_792720	28.3	1033	1047	1018	1.20e-113	375
k141_161196_9	SARG|YP_001350280	28.4	1033	1047	1018	1.20e-113	375
k141_161196_9	SARG|AAG07763	28.3	1033	1047	1018	1.20e-113	375
k141_161196_9	SARG|YP_606823	28.4	1041	1047	1011	2.78e-113	374
k141_161196_9	SARG|YP_001266290	28.0	1036	1047	1014	5.66e-113	373
k141_133870_22	SARG|gb|AAC75314.1|ARO:3003578|pmrF	33.4	308	316	322	4.72e-47	160
k141_133870_34	SARG|gi|488374619|ref|WP_002444004.1|	28.2	429	450	452	6.71e-55	188
k141_133870_34	SARG|HE999704.1.gene3064.p01	32.8	204	450	241	5.31e-34	126
k141_133870_34	SARG|gi|441475675|emb|CCQ25429.1|	34.2	152	450	211	6.64e-25	100
k141_133870_37	CARD|gb|AEX49906.1|ARO:3003583|basS	30.2	215	1362	477	7.22e-19	90.5
k141_133870_37	CARD|gb|ATC67679.1|ARO:3000838|arlR	37.6	117	1362	219	5.50e-17	80.5
k141_133870_37	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	33.9	118	1362	231	1.08e-15	77.0
k141_133870_37	CARD|gb|AAD51348.1|ARO:3003066|smeR	38.0	121	1362	229	1.40e-15	76.6
k141_133870_37	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	35.0	117	1362	252	3.90e-15	75.9
k141_133870_37	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	32.1	131	1362	223	1.17e-13	70.9
k141_133870_37	NCBI|XSG12258.1|1|1|drcS|drcS||1|||daptomycin_efflux_sensor_histidine_kinase_DrcS|AMR|peptide	30.9	152	1362	341	1.35e-10	63.5
k141_133870_37	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.1	117	1362	220	3.80e-10	60.5
k141_133870_37	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.1	117	1362	219	6.81e-10	59.7
k141_133870_37	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.1	117	1362	219	6.81e-10	59.7
k141_133870_97	SARG|gb|AAA25550.1|ARO:3003105|dfrA3	43.2	162	163	162	9.23e-39	128
k141_133870_97	NCBI|WP_049581834.1|1|1|dfrA45|dfrA45|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA45|AMR|diaminopyrimidine	41.1	163	163	164	3.93e-38	127
k141_133870_97	SARG|gb|AAO04716.1|ARO:3002865|dfrC	40.4	161	163	161	4.69e-36	121
k141_133870_97	NCBI|WP_000175735.1|1|1|dfrS1|dfrC|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrS1|AMR|diaminopyrimidine	40.4	161	163	161	6.64e-36	121
k141_133870_97	SARG|CAE53424	35.4	164	163	169	9.80e-29	103
k141_133870_97	NCBI|WP_012655890.1|1|1|dfrE|dfrE|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrE|AMR|diaminopyrimidine	34.5	165	163	164	6.05e-26	95.9
k141_133870_97	NCBI|WP_434062363.1|1|1|dfrA53|dfrA53|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA53|AMR|diaminopyrimidine	38.0	163	163	166	5.03e-25	93.6
k141_133870_97	NCBI|WP_130949671.1|1|1|dfrA50|dfrA50|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA50|AMR|diaminopyrimidine	40.2	127	163	158	4.57e-24	90.9
k141_133870_97	NCBI|WP_040203768.1|1|1|dfrA50|dfrA50|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA50|AMR|diaminopyrimidine	39.4	127	163	158	1.42e-22	87.0
k141_133870_97	SARG|gb|ABO40886.1|ARO:3004645|dfrI	38.1	160	163	191	1.56e-22	87.8
k141_133870_105	CARD|gb|AAC75137.1|ARO:3000794|mdtC	23.9	1001	1049	1025	2.23e-94	322
k141_133870_105	SARG|AAG07763	23.6	1040	1049	1018	8.67e-89	306
k141_133870_105	SARG|YP_792720	23.6	1040	1049	1018	1.63e-88	305
k141_133870_105	SARG|YP_001350280	23.5	1040	1049	1018	7.85e-88	303
k141_133870_105	SARG|YP_001266290	24.1	1048	1049	1014	9.14e-87	300
k141_133870_105	SARG|YP_001670703	24.0	1044	1049	1014	1.53e-85	297
k141_133870_105	CARD|gb|AAG07594.1|ARO:3000808|MexI	24.8	1049	1049	1029	4.81e-85	296
k141_133870_105	CARD|gb|AAC75136.1|ARO:3000793|mdtB	23.0	1025	1049	1040	4.92e-84	293
k141_133870_105	SARG|gb|AAG05914|ARO:3004075|MuxC	25.0	1034	1049	1036	2.21e-83	291
k141_133870_105	SARG|YP_606823	24.0	1039	1049	1011	1.92e-82	288
k141_133870_109	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	36.0	539	545	655	7.63e-102	320
k141_133870_109	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.8	539	545	655	2.98e-101	318
k141_133870_109	SARG|gb|AKA86814|ARO:3003746|optrA	35.8	539	545	655	2.98e-101	318
k141_133870_109	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.8	539	545	655	1.16e-100	317
k141_133870_109	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.8	539	545	655	1.16e-100	317
k141_133870_109	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.8	539	545	655	2.29e-100	316
k141_133870_109	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.8	539	545	655	2.29e-100	316
k141_133870_109	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.8	539	545	655	2.29e-100	316
k141_133870_109	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.8	539	545	655	2.29e-100	316
k141_133870_109	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.8	539	545	655	3.22e-100	315
k141_133870_110	CARD|gb|ADM92605.1|ARO:3000553|adeR	32.8	122	134	247	4.36e-11	57.4
k141_208588_13	SARG|gi|671541568|ref|WP_031525212.1|	35.0	206	236	648	3.01e-31	119
k141_208588_13	SARG|gi|694064328|ref|WP_032410816.1|	37.1	186	236	646	7.63e-31	118
k141_208588_13	SARG|gb|WP_104671188.1|ARO:3003948|efrA	29.2	185	236	575	2.28e-16	76.6
k141_208588_13	SARG|gi|926400371|ref|WP_053728483.1|	30.1	209	236	603	2.32e-16	76.6
k141_208588_13	SARG|gi|655413091|ref|WP_028811890.1|	30.5	210	236	603	7.77e-16	75.1
k141_208588_13	SARG|gi|664395661|ref|WP_030922045.1|	29.8	208	236	601	1.42e-15	74.3
k141_208588_13	SARG|gi|664458452|ref|WP_030980047.1|	30.3	208	236	601	2.60e-15	73.6
k141_208588_13	SARG|gi|930482089|ref|WP_054228897.1|	26.7	206	236	599	3.51e-15	73.2
k141_208588_13	SARG|gi|985844137|ref|WP_060895163.1|	26.7	206	236	599	3.51e-15	73.2
k141_208588_13	SARG|gi|517347347|ref|WP_018522839.1|	29.3	208	236	601	3.51e-15	73.2
k141_230412_21	SARG|gb|APB03219.1|ARO:3003986|TaeA	40.5	640	630	648	2.06e-147	440
k141_230412_21	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.2	519	630	655	6.85e-64	221
k141_230412_21	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	519	630	655	9.48e-64	221
k141_230412_21	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	519	630	655	1.31e-63	221
k141_230412_21	SARG|gb|AKA86814|ARO:3003746|optrA	31.0	519	630	655	1.31e-63	221
k141_230412_21	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	519	630	655	2.51e-63	220
k141_230412_21	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	516	630	655	6.65e-63	219
k141_230412_21	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	519	630	655	9.20e-63	218
k141_230412_21	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	519	630	655	9.20e-63	218
k141_230412_21	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	31.0	519	630	655	9.20e-63	218
k141_230412_26	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.4	230	230	231	7.30e-41	138
k141_230412_26	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	40.4	230	230	231	1.45e-40	137
k141_230412_26	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	40.4	230	230	231	1.45e-40	137
k141_230412_26	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.1	230	230	231	3.21e-39	134
k141_230412_26	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.6	230	230	231	3.21e-39	134
k141_230412_26	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.7	230	230	231	4.53e-39	134
k141_230412_26	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.7	230	230	231	6.39e-39	133
k141_230412_26	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.7	230	230	231	6.39e-39	133
k141_230412_26	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	38.6	236	230	232	5.68e-37	128
k141_230412_26	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.7	230	230	231	7.80e-37	128
k141_230412_27	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	31.0	210	599	370	2.66e-29	118
k141_230412_27	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	31.2	221	599	367	2.91e-28	115
k141_230412_27	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	31.2	221	599	368	2.95e-28	115
k141_230412_27	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	30.0	210	599	365	2.36e-27	112
k141_230412_27	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.2	212	599	381	1.36e-26	110
k141_230412_27	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.2	212	599	381	1.36e-26	110
k141_230412_27	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.2	212	599	381	6.11e-26	108
k141_230412_27	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.2	212	599	381	6.11e-26	108
k141_230412_27	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.3	221	599	381	3.69e-25	106
k141_230412_27	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.3	221	599	381	3.69e-25	106
k141_161806_7	SARG|gb|ADZ12699.1|ARO:3005091|RanA	58.1	253	257	258	4.53e-105	304
k141_161806_7	SARG|gi|983301550|ref|WP_060487860.1|	23.3	210	257	492	2.54e-07	50.1
k141_161806_7	SARG|gi|494215524|ref|WP_007131565.1|	19.7	213	257	492	2.54e-07	50.1
k141_161806_7	SARG|gi|822524709|ref|WP_046954623.1|	22.0	209	257	492	2.54e-07	50.1
k141_161806_7	SARG|gi|926250866|ref|WP_053589133.1|	21.3	211	257	492	6.10e-07	48.9
k141_161806_7	SARG|gi|516130021|ref|WP_017560601.1|	22.9	210	257	492	6.10e-07	48.9
k141_161806_7	SARG|gi|445983919|ref|WP_000061774.1|	20.4	211	257	492	1.09e-06	48.1
k141_161806_7	SARG|gb|AGN74946|ARO:3003749|salA	22.4	201	257	541	1.13e-06	48.1
k141_161806_7	SARG|gi|953356378|ref|WP_058006334.1|	21.1	209	257	492	1.46e-06	47.8
k141_161806_7	SARG|gi|445983951|ref|WP_000061806.1|	22.4	210	257	492	1.46e-06	47.8
k141_161806_8	SARG|gb|ADZ12700.1|ARO:3005090|RanB	48.6	247	248	253	2.20e-72	220
k141_161806_9	SARG|gb|AEA37904.1|ARO:3003112|lsaC	25.4	189	253	492	1.23e-09	57.0
k141_161806_27	SARG|CAP74085	40.4	52	187	210	1.02e-06	46.2
k141_50141_16	SARG|gi|1027683834|ref|WP_063622660.1|	26.3	118	126	141	1.07e-06	43.9
k141_50141_16	SARG|gi|556480341|ref|WP_023331921.1|	26.1	119	126	141	2.88e-06	42.7
k141_50141_20	SARG|gi|746609237|ref|WP_039635344.1|	35.5	324	334	322	6.58e-57	186
k141_50141_20	SARG|AAY52004	40.0	280	334	322	1.30e-56	185
k141_50141_20	SARG|CAB61228	39.7	282	334	322	7.23e-56	183
k141_50141_20	SARG|gi|749574782|ref|WP_040203616.1|	41.0	273	334	323	2.07e-55	182
k141_50141_20	SARG|gi|740152780|ref|WP_037997109.1|	35.3	323	334	322	7.93e-55	181
k141_50141_20	SARG|AF155139.2.gene6.p01	34.9	324	334	322	1.12e-54	180
k141_50141_20	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	35.1	325	334	348	4.36e-54	179
k141_50141_20	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	35.4	325	334	343	5.39e-54	179
k141_50141_20	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	37.3	295	334	323	6.34e-54	178
k141_50141_20	SARG|AF310956.2.gene5.p01	37.3	295	334	323	8.92e-54	178
k141_50141_34	SARG|U19459.gene.p01	34.2	117	188	212	4.49e-12	61.2
k141_50141_34	SARG|GQ205627.2.gene3.p01	36.2	130	188	216	1.24e-11	60.1
k141_50141_34	SARG|gb|APB03220.1|ARO:3003987|VatI	37.2	113	188	210	1.60e-11	59.7
k141_50141_34	SARG|YP_002861121	52.9	51	188	212	4.30e-11	58.5
k141_129772_6	SARG|gb|WP_081853183.1|ARO:3006885|ELM-1	30.9	94	213	313	1.12e-07	50.1
k141_129772_6	NCBI|WP_015048279.1|1|1|blaSAM-1|blaSAM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_SAM-1|AMR|beta-lactam	25.2	159	213	295	1.58e-06	46.6
k141_129772_6	SARG|gb|AYD68552.1|ARO:3005018|LMB-1	29.1	103	213	304	9.64e-06	44.3
k141_129772_41	megares|MEG_7174|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.6	436	595	629	2.93e-24	106
k141_129772_41	SARG|gi|1004359922|gb|AMP42228.1|	26.1	437	595	639	3.01e-24	106
k141_129772_41	ResF|tet(O/W)_2_AM889119_1	26.6	436	595	639	3.01e-24	106
k141_129772_41	megares|MEG_7173|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.1	436	595	629	2.14e-23	103
k141_129772_41	ResF|tet(O/W)_1_AM889118_1	26.1	436	595	639	2.20e-23	103
k141_129772_41	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.1	436	595	629	2.85e-23	103
k141_129772_41	ResF|tet(O/W)_4_AM889121_1	26.1	436	595	639	2.92e-23	103
k141_129772_41	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	26.2	439	595	629	8.86e-23	101
k141_129772_41	SARG|gi|164612278|gb|ABY63608.1|	24.3	432	595	639	9.09e-23	101
k141_129772_41	SARG|ABB70049	24.3	432	595	639	9.09e-23	101
k141_129772_49	NCBI|WP_063844229.1|1|1|cmlV|cmlV|efflux|2|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_MFS_transporter_CmlV|AMR|phenicol	32.4	364	381	412	9.63e-48	166
k141_129772_49	SARG|U09991.1.gene2.p01	32.4	364	381	436	1.58e-47	166
k141_129772_49	megares|MEG_1780|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMRA_1	29.9	344	381	391	7.66e-40	144
k141_129772_49	SARG|AF015087.1.gene1.p01	29.9	344	381	391	7.66e-40	144
k141_129772_49	SARG|gb|CAA78046.1|ARO:3002701|Rfas_cmr	29.2	356	381	391	1.49e-37	138
k141_129772_49	megares|MEG_1781|Drugs|Phenicol|Phenicol_resistance_MFS_efflux_pumps|CMRA_1	29.2	356	381	391	1.49e-37	138
k141_67901_14	NCBI|AAN33535.1|1|1|bepF|bepF|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_BepF|AMR|efflux	38.2	322	417	411	1.09e-56	191
k141_67901_14	NCBI|AAD15663.1|1|1|tbtA|tbtA|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_TbtA|AMR|efflux	34.2	339	417	382	2.07e-50	173
k141_67901_14	SARG|NC_009085.4918693.p01	32.0	341	417	376	1.88e-49	171
k141_67901_14	SARG|gi|183210901|gb|ACC58299.1|	32.0	341	417	415	4.52e-49	171
k141_67901_14	SARG|NC_010400.5984386.p01	32.0	341	417	415	4.52e-49	171
k141_67901_14	SARG|NC_011586.7045443.p01	32.0	341	417	416	4.62e-49	171
k141_67901_14	SARG|gi|505289665|ref|WP_015476767.1|	33.9	345	417	411	1.57e-48	169
k141_67901_14	SARG|gi|497308478|ref|WP_009622695.1|	33.4	350	417	410	8.38e-47	164
k141_67901_14	SARG|gi|759552006|ref|WP_043271822.1|	33.7	362	417	410	3.17e-46	163
k141_67901_14	SARG|gi|639919893|ref|WP_024762275.1|	32.1	364	417	411	8.75e-46	162
k141_67901_15	NCBI|AAN29241.1|1|1|bepE|bepE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepE|AMR|efflux	43.0	1039	1037	1051	1.75e-270	785
k141_67901_15	NCBI|AAN33534.1|1|1|bepG|bepG|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepG|AMR|efflux	42.8	1037	1037	1074	1.44e-269	783
k141_67901_15	SARG|gi|950554518|ref|WP_057427257.1|	41.8	1044	1037	1060	5.26e-266	774
k141_67901_15	SARG|gi|940169821|gb|KPX83830.1|	41.9	1032	1037	1059	5.75e-262	763
k141_67901_15	SARG|gi|685895165|ref|WP_031636098.1|	41.5	1041	1037	1062	5.02e-261	761
k141_67901_15	SARG|gi|553764341|ref|WP_023096686.1|	41.4	1041	1037	1062	7.09e-261	761
k141_67901_15	SARG|gi|550043906|ref|WP_022580472.1|	41.5	1041	1037	1062	7.09e-261	761
k141_67901_15	SARG|gi|544849761|ref|WP_021264856.1|	41.5	1041	1037	1062	1.00e-260	760
k141_67901_15	SARG|gi|844727272|ref|WP_047925316.1|	41.4	1041	1037	1062	1.00e-260	760
k141_67901_15	SARG|gi|512743205|ref|WP_016499908.1|	41.7	1042	1037	1059	1.29e-260	760
k141_67901_16	SARG|CAR56415	29.9	492	467	519	1.60e-63	213
k141_67901_16	SARG|gi|493540358|ref|WP_006494234.1|	29.9	492	467	511	1.88e-63	213
k141_67901_16	SARG|YP_001811889	30.2	474	467	513	1.97e-63	213
k141_67901_16	SARG|YP_622885	30.4	474	467	513	3.84e-63	212
k141_67901_16	SARG|YP_001116030	30.4	474	467	517	4.19e-63	212
k141_67901_16	SARG|YP_001778540	30.9	473	467	513	7.51e-63	211
k141_67901_16	SARG|ZP_02904979	29.7	474	467	511	1.40e-62	210
k141_67901_16	SARG|YP_001949526	29.9	492	467	511	1.40e-62	210
k141_67901_16	SARG|YP_776581	29.7	474	467	513	1.47e-62	210
k141_67901_16	SARG|ZP_02889082	29.7	474	467	513	1.47e-62	210
k141_67901_53	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	33.6	116	1437	231	8.93e-18	83.2
k141_67901_53	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	36.8	114	1437	232	3.07e-17	81.6
k141_67901_53	CARD|gb|AEX49906.1|ARO:3003583|basS	25.0	236	1437	477	6.97e-12	68.6
k141_77824_3	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	44.0	50	97	346	2.69e-08	48.5
k141_77824_14	SARG|gb|APB03220.1|ARO:3003987|VatI	35.4	113	192	210	1.80e-12	62.4
k141_77824_14	SARG|GQ205627.2.gene3.p01	33.8	139	192	216	5.13e-12	61.2
k141_77824_14	SARG|U19459.gene.p01	33.9	115	192	212	3.38e-11	58.9
k141_77824_14	SARG|M58472.1.gene1.p01	31.7	104	192	209	2.85e-09	53.5
k141_77824_14	SARG|YP_002861121	47.1	51	192	212	1.04e-08	52.0
k141_77824_21	CARD|gb|AAC75429.1|ARO:3000833|evgS	23.0	443	772	1197	6.08e-32	132
k141_77824_22	CARD|gb|AAK37618.1|ARO:3005008|TxR	39.5	296	428	318	3.92e-56	187
k141_104704_8	SARG|FJ872411.1.gene41.p01	32.0	338	325	352	1.03e-53	178
k141_104704_8	SARG|gb|ABX54687.1|ARO:3002910|vanL	30.6	337	325	349	1.22e-50	170
k141_104704_8	SARG|gi|498467695|ref|WP_010773051.1|	29.8	339	325	352	1.85e-50	170
k141_104704_8	SARG|gi|752682279|ref|WP_041330231.1|	31.2	343	325	349	3.66e-49	166
k141_104704_8	SARG|gi|1028100561|ref|WP_063856696.1|	30.5	344	325	349	3.66e-49	166
k141_104704_8	SARG|JF802084.2.gene1.p01	29.7	340	325	343	2.43e-48	164
k141_104704_8	NCBI|PBI24747.1|1|1|vanG-Cd|vanG-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--D-serine_ligase_VanG-Cd|AMR|glycopeptide	28.9	360	325	366	2.27e-47	162
k141_104704_8	SARG|DQ212986.1.gene8.p01	29.9	344	325	349	1.17e-46	160
k141_104704_8	SARG|gi|405945042|pdb|4FU0|A	29.9	344	325	357	1.40e-46	160
k141_104704_8	SARG|gi|765411304|ref|WP_044689514.1|	29.9	344	325	349	2.29e-46	159
k141_104704_30	SARG|AUI09862.1	36.0	272	291	287	1.53e-49	164
k141_104704_30	SARG|gi|638947703|ref|WP_024439711.1|	30.4	263	291	271	5.90e-29	110
k141_104704_31	megares|MEG_7572|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	30.4	438	452	481	1.37e-52	182
k141_104704_31	megares|MEG_7571|Drugs|Glycopeptide|VanM-type_resistance_protein|VANXM_2	30.6	435	452	451	2.78e-52	181
k141_104704_31	megares|MEG_7563|Drugs|Glycopeptide|VanB-type_resistance_protein|VANXB_2	29.6	432	452	451	5.63e-50	175
k141_104704_35	SARG|gi|896325272|ref|WP_049294291.1|	46.6	219	219	648	7.54e-60	197
k141_104704_35	SARG|gi|639216333|ref|WP_024554080.1|	46.1	219	219	648	2.05e-59	196
k141_104704_35	SARG|gi|639225329|ref|WP_024561799.1|	46.1	219	219	648	1.51e-58	194
k141_104704_35	SARG|gi|639218559|ref|WP_024556062.1|	46.1	219	219	648	1.51e-58	194
k141_104704_35	SARG|gi|657888313|ref|WP_029592374.1|	45.2	219	219	648	1.11e-57	191
k141_104704_35	SARG|gi|671541568|ref|WP_031525212.1|	46.1	219	219	648	3.00e-57	190
k141_104704_35	SARG|gi|803568669|ref|WP_046077412.1|	45.2	219	219	648	5.82e-57	189
k141_104704_35	SARG|gi|446110352|ref|WP_000188207.1|	45.2	219	219	648	5.82e-57	189
k141_104704_35	SARG|YP_002382193	45.2	219	219	648	5.82e-57	189
k141_104704_35	SARG|gi|803575554|ref|WP_046081557.1|	45.2	219	219	648	5.82e-57	189
k141_104704_60	megares|MEG_5409|Drugs|beta-lactam|Penicillin_binding_protein|PBP4B_1	31.2	398	610	434	2.15e-50	179
k141_104704_70	CARD|gb|AAC75429.1|ARO:3000833|evgS	28.5	403	1279	1197	5.02e-38	154
k141_104704_70	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.2	119	1279	219	1.15e-19	88.2
k141_104704_70	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	32.6	138	1279	232	3.21e-18	84.3
k141_104704_70	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	35.9	117	1279	228	2.48e-17	81.6
k141_104704_70	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	34.2	117	1279	231	3.57e-17	81.3
k141_104704_70	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	28.1	146	1279	233	2.58e-15	75.9
k141_104704_70	CARD|gb|AAG06465.1|ARO:3005063|cprR	33.9	121	1279	223	2.41e-14	72.8
k141_104704_70	CARD|gb|ADM92605.1|ARO:3000553|adeR	35.0	120	1279	247	3.69e-14	72.8
k141_104704_70	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	32.5	117	1279	235	1.83e-13	70.5
k141_104704_70	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	26.5	151	1279	232	5.80e-13	68.9
k141_104704_103	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	27.6	362	708	674	9.01e-19	89.7
k141_104704_103	SARG|gb|BAI83385.1|ARO:3003440|mecB	27.6	362	708	674	1.19e-18	89.4
k141_104704_103	NCBI|WP_069996660.1|1|1|mecC3|mecC3|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC3|AMR|beta-lactam	22.7	428	708	665	2.11e-15	79.0
k141_104704_103	megares|MEG_3800|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	22.8	447	708	665	8.43e-15	77.0
k141_104704_103	NCBI|WP_128268231.1|1|1|mecC2|mecC2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC2|AMR|beta-lactam	23.2	427	708	665	2.55e-14	75.5
k141_104704_103	NCBI|WP_063852694.1|1|1|mecA2|mecA2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecA2|AMR|beta-lactam	24.1	452	708	668	5.87e-14	74.3
k141_104704_103	SARG|gi|486697816|ref|WP_001620256.1|	22.9	507	708	668	1.77e-13	72.8
k141_104704_103	SARG|gi|446643961|ref|WP_000721307.1|	22.7	507	708	668	1.77e-13	72.8
k141_104704_103	SARG|gi|487387906|ref|WP_001659608.1|	22.7	507	708	668	2.34e-13	72.4
k141_104704_103	SARG|gi|916178542|ref|WP_050963202.1|	22.7	507	708	668	2.34e-13	72.4
k141_104704_116	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	40.5	686	654	703	1.37e-157	469
k141_104704_153	SARG|gi|928900436|ref|WP_053931243.1|	36.7	526	613	600	8.60e-103	323
k141_104704_153	SARG|gi|664579989|ref|WP_031094015.1|	36.7	526	613	601	8.84e-103	323
k141_104704_153	SARG|gb|AAC74000.1|ARO:3003950|msbA	36.5	509	613	582	6.22e-101	317
k141_104704_153	SARG|gi|497748188|ref|WP_010062372.1|	35.9	529	613	605	8.85e-100	315
k141_104704_153	SARG|gi|663330365|ref|WP_030329892.1|	35.9	529	613	607	9.33e-100	315
k141_104704_153	SARG|gi|948137056|ref|WP_056795395.1|	35.7	529	613	602	1.15e-99	315
k141_104704_153	SARG|gi|944009777|ref|WP_055601444.1|	36.1	499	613	628	1.61e-99	315
k141_104704_153	SARG|gi|648667297|ref|WP_026359044.1|	35.0	523	613	605	2.45e-99	314
k141_104704_153	SARG|gi|764446018|ref|WP_044369325.1|	35.7	529	613	605	2.45e-99	314
k141_104704_153	SARG|gi|663155409|ref|WP_030194633.1|	35.7	529	613	605	2.45e-99	314
k141_104704_155	SARG|gb|AAC75314.1|ARO:3003578|pmrF	33.9	124	302	322	2.13e-08	53.5
k141_104704_165	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	28.0	289	350	351	4.78e-24	100
k141_104704_165	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	28.7	286	350	343	1.02e-22	96.3
k141_104704_165	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	28.7	286	350	348	1.08e-22	96.3
k141_104704_165	SARG|YP_002333394	30.8	234	350	323	2.01e-22	95.1
k141_104704_165	SARG|AF310956.2.gene5.p01	30.8	234	350	323	2.75e-22	94.7
k141_104704_165	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	30.8	234	350	323	2.75e-22	94.7
k141_104704_165	SARG|gi|498515089|ref|WP_010815296.1|	31.2	234	350	323	7.10e-22	93.6
k141_104704_165	SARG|gb|AAB05626.1|ARO:3002943|vanHB	30.8	234	350	323	7.10e-22	93.6
k141_104704_165	SARG|AF155139.2.gene6.p01	31.2	205	350	322	9.60e-22	93.2
k141_104704_165	SARG|Q47748	30.8	234	350	323	1.33e-21	92.8
k141_104704_180	SARG|gi|487083213|ref|WP_001626199.1|	29.6	379	392	385	1.58e-43	154
k141_104704_180	SARG|gi|447004741|ref|WP_001081997.1|	28.4	377	392	385	2.20e-43	154
k141_104704_180	SARG|NC_002695.1.915750.p01	28.4	377	392	385	3.07e-43	154
k141_104704_180	SARG|gi|486353230|ref|WP_001590854.1|	29.0	379	392	385	5.96e-43	153
k141_104704_180	SARG|gi|447004723|ref|WP_001081979.1|	29.0	379	392	385	5.96e-43	153
k141_104704_180	SARG|gi|486394471|ref|WP_001604024.1|	28.1	377	392	385	5.96e-43	153
k141_104704_180	SARG|gi|391257401|gb|EIQ16513.1|	29.0	379	392	385	8.31e-43	152
k141_104704_180	SARG|gi|657329748|ref|WP_029396991.1|	29.0	379	392	385	8.31e-43	152
k141_104704_180	SARG|gi|447004742|ref|WP_001081998.1|	28.4	377	392	385	8.31e-43	152
k141_104704_180	SARG|gi|487418604|ref|WP_001685632.1|	29.0	379	392	385	1.16e-42	152
k141_104704_181	NCBI|AAN29241.1|1|1|bepE|bepE|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepE|AMR|efflux	39.0	1109	1139	1051	1.48e-242	717
k141_104704_181	NCBI|AAN33534.1|1|1|bepG|bepG|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepG|AMR|efflux	38.6	1119	1139	1074	1.50e-232	692
k141_104704_181	CARD|gb|ABS43151.1|ARO:3000784|cmeB	37.5	1124	1139	1040	3.87e-226	674
k141_104704_181	NCBI|WP_254563251.1|1|1|cmeB_RE|cmeB_RE|efflux|2|FLORFENICOL/quinolone|PHENICOL/quinolone|multidrug_efflux_RND_transporter_permease_subunit_CmeB,_ciprofloxacin_and_phenicol_resistance_type|AMR|multidrug	38.1	1120	1139	1039	3.94e-222	664
k141_104704_181	SARG|gi|966476691|ref|WP_058507424.1|	36.1	1134	1139	1063	1.55e-214	645
k141_104704_181	SARG|CP000675.2.gene2723.p01	36.4	1136	1139	1050	8.26e-214	642
k141_104704_181	SARG|gi|517405910|ref|WP_018578567.1|	37.6	1134	1139	1064	8.82e-214	643
k141_104704_181	SARG|gi|654923461|ref|WP_028373991.1|	35.5	1156	1139	1069	1.72e-211	637
k141_104704_181	SARG|gi|966461601|ref|WP_058493954.1|	36.1	1136	1139	1054	3.11e-211	636
k141_104704_181	SARG|gi|966506160|ref|WP_058522806.1|	35.9	1134	1139	1066	3.13e-211	636
k141_104704_182	SARG|NC_008702.1.4607681.p01	29.5	461	460	469	3.17e-41	152
k141_104704_182	SARG|YP_002706078	28.7	414	460	481	1.37e-35	136
k141_104704_182	SARG|gi|544780240|ref|WP_021203903.1|	28.6	413	460	461	1.43e-35	136
k141_104704_182	SARG|CAC14596	27.6	453	460	466	1.54e-35	136
k141_104704_182	SARG|CAG34251	28.1	413	460	466	5.45e-35	134
k141_104704_182	SARG|gb|AAL19304.1|ARO:3000791|mdsC	27.6	463	460	503	1.19e-34	134
k141_104704_182	SARG|YP_001973746	27.8	413	460	466	1.41e-34	133
k141_104704_182	SARG|gi|491553496|ref|WP_005411087.1|	27.8	413	460	461	1.81e-34	133
k141_104704_182	SARG|CP001138.1.gene376.p01	27.4	463	460	485	4.61e-34	132
k141_104704_182	SARG|gi|353074765|gb|EHB40525.1|	27.0	460	460	496	5.25e-34	132
k141_104704_186	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.1	231	1357	381	2.85e-21	96.7
k141_104704_186	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.1	231	1357	381	2.85e-21	96.7
k141_104704_186	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.9	233	1357	381	3.82e-21	96.3
k141_104704_186	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.9	233	1357	381	3.82e-21	96.3
k141_104704_186	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.1	231	1357	381	9.22e-21	95.1
k141_104704_186	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.1	231	1357	381	9.22e-21	95.1
k141_104704_186	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.1	231	1357	381	9.22e-21	95.1
k141_104704_186	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.1	231	1357	381	9.22e-21	95.1
k141_104704_186	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.7	231	1357	381	7.17e-20	92.4
k141_104704_186	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.7	231	1357	381	7.17e-20	92.4
k141_104704_250	SARG|ZP_04606269	26.2	145	177	299	1.73e-08	51.6
k141_104704_286	SARG|ZP_04055725	59.3	280	285	283	8.65e-99	290
k141_104704_286	SARG|ZP_04528247	42.2	282	285	279	2.73e-62	197
k141_104704_286	SARG|YP_932216	44.6	269	285	274	2.66e-58	186
k141_104704_286	SARG|YP_001187667	43.0	270	285	276	1.12e-57	185
k141_104704_286	SARG|YP_316450	44.0	284	285	276	1.59e-57	184
k141_104704_286	SARG|CAY49038	42.1	273	285	276	2.24e-57	184
k141_104704_286	SARG|NP_840140	42.3	284	285	273	2.90e-57	184
k141_104704_286	SARG|B7VAE6	44.2	269	285	277	4.60e-57	183
k141_104704_286	SARG|YP_608499	43.2	273	285	276	8.91e-57	182
k141_104704_286	SARG|YP_791281	43.9	269	285	277	1.29e-56	182
k141_104704_309	SARG|gi|671541568|ref|WP_031525212.1|	23.0	230	254	648	7.00e-15	72.8
k141_104704_309	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	26.9	234	254	505	5.13e-14	70.1
k141_104704_309	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	28.4	194	254	504	9.32e-14	69.3
k141_104704_309	SARG|gi|488243106|ref|WP_002314314.1|	30.7	192	254	492	1.24e-13	68.9
k141_104704_309	SARG|gi|488321355|ref|WP_002390740.1|	30.7	192	254	492	5.53e-13	67.0
k141_104704_309	SARG|gi|488231473|ref|WP_002302681.1|	29.7	192	254	492	1.35e-12	65.9
k141_104704_309	SARG|gi|488216250|ref|WP_002287458.1|	29.7	192	254	492	1.35e-12	65.9
k141_104704_309	SARG|gi|488247627|ref|WP_002318835.1|	29.7	192	254	492	1.35e-12	65.9
k141_104704_309	SARG|AY004350.gene.p01	29.7	192	254	492	1.35e-12	65.9
k141_104704_309	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	24.6	236	254	568	2.25e-10	59.3
k141_242461_27	NCBI|BAB64566.1|1|1|bexA|bexA|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_BexA|AMR|efflux	45.2	440	440	443	1.51e-135	395
k141_242461_36	CARD|gb|AAC75429.1|ARO:3000833|evgS	30.8	390	1052	1197	1.73e-47	184
k141_242461_36	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	34.5	119	1052	232	8.45e-13	68.2
k141_242461_36	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	34.7	118	1052	231	2.05e-12	67.0
k141_242461_36	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.2	116	1052	228	1.76e-10	61.2
k141_242461_36	CARD|gb|ADM92605.1|ARO:3000553|adeR	23.3	120	1052	247	1.35e-09	58.9
k141_242461_38	CARD|gb|ABD30512.1|ARO:3000839|arlS	28.6	224	569	451	3.50e-20	92.4
k141_242461_39	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	32.8	238	240	231	7.83e-40	136
k141_242461_39	CARD|gb|ATC67679.1|ARO:3000838|arlR	32.0	231	240	219	3.03e-36	126
k141_242461_39	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	30.0	237	240	232	5.52e-33	118
k141_242461_39	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.9	235	240	228	4.51e-30	110
k141_242461_39	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	28.8	236	240	231	2.14e-27	103
k141_242461_39	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	28.8	236	240	231	3.00e-27	103
k141_242461_39	CARD|gb|AAG06465.1|ARO:3005063|cprR	29.9	234	240	223	3.51e-27	103
k141_242461_39	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	28.8	236	240	231	4.20e-27	103
k141_242461_39	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	28.8	236	240	233	8.62e-27	102
k141_242461_39	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	29.2	233	240	231	1.16e-26	102
k141_242461_62	NCBI|BAB64566.1|1|1|bexA|bexA|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_BexA|AMR|efflux	73.4	443	444	443	1.56e-238	657
k141_242461_69	SARG|gi|671541568|ref|WP_031525212.1|	29.2	113	943	648	1.42e-07	54.3
k141_242461_69	SARG|gi|1035706844|ref|WP_064548272.1|	34.2	76	943	648	8.61e-06	48.5
k141_242461_81	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	41.0	117	376	229	6.72e-21	89.4
k141_242461_81	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	38.8	116	376	230	8.71e-20	86.3
k141_242461_81	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	34.9	146	376	233	3.26e-19	84.7
k141_242461_81	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.8	117	376	231	1.11e-18	83.2
k141_242461_81	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.8	117	376	231	2.08e-18	82.4
k141_242461_81	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.8	117	376	231	2.85e-18	82.0
k141_242461_81	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.8	117	376	231	3.90e-18	81.6
k141_242461_81	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	40.2	117	376	235	5.73e-18	81.3
k141_242461_81	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	36.2	116	376	231	6.50e-17	78.2
k141_242461_81	CARD|gb|ADM92605.1|ARO:3000553|adeR	32.9	149	376	247	8.46e-17	78.2
k141_198632_7	SARG|gi|447195835|ref|WP_001273091.1|	32.9	240	253	306	3.72e-34	124
k141_198632_7	SARG|gi|542061059|gb|ERI11611.1|	33.2	217	253	316	6.40e-34	123
k141_198632_7	SARG|ZP_04081918	32.5	240	253	306	1.02e-33	122
k141_198632_7	SARG|gi|447195836|ref|WP_001273092.1|	32.5	240	253	306	1.02e-33	122
k141_198632_7	SARG|gi|500448961|gb|EOP61695.1|	31.4	220	253	306	5.50e-33	120
k141_198632_7	SARG|gi|500465078|gb|EOP76697.1|	31.4	220	253	306	1.08e-32	120
k141_198632_7	SARG|gi|488068784|ref|WP_002140181.1|	32.7	220	253	309	1.67e-31	117
k141_198632_7	SARG|YP_001373621	31.8	220	253	318	1.99e-31	117
k141_198632_7	SARG|gi|500194536|ref|WP_011867743.1|	31.2	218	253	306	2.21e-31	116
k141_198632_7	SARG|gi|507023808|ref|WP_016095885.1|	32.3	220	253	309	2.34e-31	116
k141_115516_38	CARD|gb|AAC75429.1|ARO:3000833|evgS	33.7	276	625	1197	1.27e-35	142
k141_115516_38	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.1	251	625	354	2.69e-17	82.8
k141_115516_38	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.9	224	625	354	3.61e-17	82.4
k141_115516_38	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.5	224	625	352	1.14e-16	80.9
k141_115516_58	SARG|ZP_04612558	59.3	388	404	404	2.28e-156	446
k141_115516_58	SARG|ZP_04631862	59.5	388	404	404	2.28e-156	446
k141_115516_58	SARG|ZP_04638972	59.0	388	404	404	6.51e-156	444
k141_115516_58	SARG|YP_001477378	57.9	397	404	406	6.97e-156	444
k141_115516_58	SARG|ZP_04621517	58.8	388	404	404	5.29e-155	442
k141_115516_58	SARG|ZP_04623896	59.9	379	404	380	9.31e-155	441
k141_115516_58	SARG|YP_001401993	58.2	388	404	404	2.46e-153	438
k141_115516_58	SARG|YP_001605796	58.0	388	404	404	9.96e-153	436
k141_115516_58	SARG|YP_001871501	57.7	388	404	404	8.09e-152	434
k141_115516_58	SARG|AAC60781	56.9	390	404	410	3.75e-139	402
k141_115516_61	CARD|gb|AAC75429.1|ARO:3000833|evgS	27.6	387	535	1197	2.71e-38	149
k141_115516_62	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	30.5	118	148	225	4.75e-09	52.0
k141_115516_62	CARD|gb|AAC73788.1|ARO:3003841|kdpE	30.5	118	148	225	4.75e-09	52.0
k141_206391_7	CARD|gb|AAC75135.2|ARO:3000792|mdtA	21.9	315	341	415	8.46e-08	52.4
k141_206391_8	CARD|gb|AAG03548.1|ARO:3003681|TriC	29.1	992	1012	1015	1.59e-134	430
k141_206391_8	SARG|gb|AAG07064.1|ARO:3003693|mexK	28.5	1016	1012	1025	2.86e-133	427
k141_206391_8	CARD|gb|AAC75136.1|ARO:3000793|mdtB	22.6	1036	1012	1040	1.84e-58	217
k141_206391_8	SARG|CAY49157	23.1	1058	1012	1059	2.70e-57	214
k141_206391_8	SARG|gi|497896441|ref|WP_010210597.1|	22.9	1058	1012	1059	1.14e-56	212
k141_206391_8	SARG|ZP_02371789	23.0	1065	1012	1061	2.03e-56	211
k141_206391_8	SARG|gi|492246796|ref|WP_005788492.1|	23.0	1061	1012	1059	2.69e-56	211
k141_206391_8	SARG|gi|803453816|ref|WP_046068030.1|	23.0	1061	1012	1059	2.69e-56	211
k141_206391_8	SARG|ABC36050	23.0	1065	1012	1061	2.71e-56	211
k141_206391_8	SARG|gi|489327637|ref|WP_003234928.1|	22.9	1057	1012	1059	4.77e-56	210
k141_206391_15	SARG|gi|488374619|ref|WP_002444004.1|	24.8	423	457	452	4.15e-40	148
k141_206391_26	SARG|gi|970323543|ref|WP_058689592.1|	23.5	405	468	492	5.88e-15	75.9
k141_206391_26	SARG|gi|772616100|ref|WP_045261912.1|	23.2	405	468	492	1.04e-14	75.1
k141_206391_26	SARG|gi|1028097694|ref|WP_063854391.1|	23.2	405	468	492	1.04e-14	75.1
k141_206391_26	SARG|gi|550766066|ref|WP_022649426.1|	23.2	405	468	492	1.04e-14	75.1
k141_206391_26	SARG|gi|1022700456|ref|WP_063451151.1|	23.2	405	468	492	1.04e-14	75.1
k141_206391_26	SARG|gi|1028113628|ref|WP_063867721.1|	23.8	408	468	492	1.04e-14	75.1
k141_206391_26	SARG|gi|823296414|ref|WP_047051998.1|	23.2	405	468	492	1.04e-14	75.1
k141_206391_26	SARG|gi|1028221825|ref|WP_063963387.1|	23.2	405	468	492	1.04e-14	75.1
k141_206391_26	SARG|gi|1016946559|ref|WP_063147892.1|	23.2	405	468	492	1.04e-14	75.1
k141_206391_26	SARG|gi|556416107|ref|WP_023306968.1|	23.2	405	468	492	1.04e-14	75.1
k141_206391_27	SARG|gi|488899926|ref|WP_002811019.1|	29.0	362	412	385	4.94e-30	118
k141_206391_27	SARG|gi|488872078|ref|WP_002784303.1|	29.3	362	412	385	6.79e-30	118
k141_206391_27	SARG|gi|488868725|ref|WP_002780964.1|	29.3	362	412	385	6.79e-30	118
k141_206391_27	SARG|gi|1036665709|ref|WP_064719478.1|	29.7	354	412	369	3.59e-29	115
k141_206391_27	SARG|gi|751930064|ref|WP_041144772.1|	28.4	349	412	371	4.70e-28	112
k141_206391_27	SARG|CP000768.1.gene1024.p01	28.1	399	412	390	6.15e-28	112
k141_206391_27	SARG|gi|695814116|ref|WP_032727988.1|	27.5	349	412	371	1.66e-27	111
k141_206391_27	SARG|gi|797192321|ref|WP_045854631.1|	28.1	349	412	371	2.28e-27	110
k141_206391_27	SARG|gi|836565950|ref|WP_047724203.1|	27.0	382	412	371	2.28e-27	110
k141_206391_27	SARG|gi|896016302|ref|WP_049079560.1|	27.5	349	412	371	3.13e-27	110
k141_206391_28	SARG|gi|968563772|ref|WP_058587854.1|	46.7	227	249	648	9.39e-65	211
k141_206391_28	SARG|gi|754927849|ref|WP_042284850.1|	46.7	227	249	648	1.83e-64	211
k141_206391_28	SARG|gi|763407609|ref|WP_044264203.1|	45.9	229	249	648	2.56e-64	210
k141_206391_28	SARG|gi|757782629|ref|WP_043001213.1|	46.3	227	249	648	5.01e-64	209
k141_206391_28	SARG|gi|992390012|ref|WP_061077002.1|	46.9	224	249	648	7.00e-64	209
k141_206391_28	SARG|gi|754964360|ref|WP_042320280.1|	46.1	228	249	648	9.78e-64	209
k141_206391_28	SARG|gi|764278838|ref|WP_044327089.1|	45.9	229	249	648	1.37e-63	208
k141_206391_28	SARG|gi|502669352|ref|WP_012905216.1|	45.6	228	249	648	2.67e-63	207
k141_206391_28	SARG|gi|823326845|ref|WP_047080664.1|	48.0	227	249	648	3.73e-63	207
k141_206391_28	SARG|gi|817104523|ref|WP_046477871.1|	46.9	224	249	648	3.73e-63	207
k141_206391_29	SARG|gb|AAV85982.1|ARO:3000535|macB	39.7	401	407	644	1.44e-77	251
k141_206391_29	SARG|gi|487359045|ref|WP_001634240.1|	38.3	399	407	648	5.29e-73	239
k141_206391_29	SARG|gi|485890120|ref|WP_001482667.1|	38.3	399	407	648	5.29e-73	239
k141_206391_29	SARG|gi|446110290|ref|WP_000188145.1|	38.3	399	407	648	1.45e-72	238
k141_206391_29	SARG|gi|654658955|ref|WP_028119847.1|	38.3	399	407	648	1.45e-72	238
k141_206391_29	SARG|gi|921979807|ref|WP_053271336.1|	38.3	399	407	648	1.45e-72	238
k141_206391_29	SARG|YP_002328441	38.3	399	407	648	1.45e-72	238
k141_206391_29	SARG|gi|485866062|ref|WP_001464282.1|	38.1	399	407	648	2.83e-72	237
k141_206391_29	SARG|gi|487410704|ref|WP_001678420.1|	38.1	399	407	648	2.83e-72	237
k141_206391_29	SARG|gi|693138751|ref|WP_032280630.1|	38.1	399	407	648	5.53e-72	236
k141_126688_14	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.9	116	120	228	4.14e-18	75.5
k141_126688_14	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	37.6	117	120	229	6.18e-17	72.4
k141_126688_14	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.6	116	120	231	6.60e-16	69.7
k141_126688_14	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.6	116	120	231	9.21e-16	69.3
k141_126688_14	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.6	116	120	231	9.21e-16	69.3
k141_126688_14	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	34.2	117	120	230	1.27e-15	68.9
k141_126688_14	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	33.6	116	120	233	3.58e-15	67.8
k141_126688_14	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	33.6	116	120	235	3.67e-15	67.8
k141_126688_14	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	31.0	116	120	231	1.83e-14	65.9
k141_126688_14	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	33.6	116	120	239	7.55e-14	64.3
k141_126688_54	SARG|gi|1035686596|ref|WP_064530178.1|	22.2	334	431	648	9.97e-08	53.1
k141_126688_54	SARG|gi|969848384|ref|WP_058609247.1|	21.5	321	431	646	9.26e-07	50.1
k141_126688_58	SARG|gi|502669352|ref|WP_012905216.1|	45.6	217	222	648	2.21e-60	199
k141_126688_58	SARG|gi|992390012|ref|WP_061077002.1|	45.6	217	222	648	3.09e-60	198
k141_126688_58	SARG|gi|754927849|ref|WP_042284850.1|	45.2	217	222	648	3.09e-60	198
k141_126688_58	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	45.4	218	222	255	6.45e-60	187
k141_126688_58	SARG|gi|757782629|ref|WP_043001213.1|	45.2	217	222	648	8.40e-60	197
k141_126688_58	SARG|gi|763407609|ref|WP_044264203.1|	45.2	217	222	648	8.40e-60	197
k141_126688_58	SARG|gi|968563772|ref|WP_058587854.1|	45.2	217	222	648	1.17e-59	197
k141_126688_58	SARG|gi|555268037|ref|WP_023249477.1|	44.5	220	222	648	2.28e-59	196
k141_126688_58	SARG|gi|835330218|ref|WP_047457825.1|	45.6	217	222	648	2.28e-59	196
k141_126688_58	SARG|YP_001453760	45.6	217	222	648	2.28e-59	196
k141_126688_59	SARG|gi|447124490|ref|WP_001201746.1|	27.0	196	416	372	1.58e-09	58.2
k141_126688_59	SARG|gi|513039047|ref|WP_016506940.1|	27.0	196	416	372	2.10e-09	57.8
k141_126688_59	SARG|gi|555286736|ref|WP_023261332.1|	26.0	196	416	372	2.80e-09	57.4
k141_126688_59	SARG|gi|685229333|ref|WP_031601964.1|	26.5	196	416	372	3.73e-09	57.0
k141_126688_59	SARG|gi|554925058|ref|WP_023197082.1|	26.5	196	416	372	3.73e-09	57.0
k141_126688_59	SARG|gi|930172076|ref|WP_054175077.1|	26.5	196	416	372	3.73e-09	57.0
k141_126688_59	SARG|gi|553809962|ref|WP_023136812.1|	26.5	196	416	372	3.73e-09	57.0
k141_126688_59	SARG|gi|555230037|ref|WP_023217515.1|	26.5	196	416	372	3.73e-09	57.0
k141_126688_59	SARG|gi|447124499|ref|WP_001201755.1|	26.5	196	416	372	3.73e-09	57.0
k141_126688_59	SARG|gi|447124489|ref|WP_001201745.1|	26.5	196	416	372	3.73e-09	57.0
k141_126688_63	SARG|gb|ABX00624.1|ARO:3002881|lmrC	35.6	526	534	550	4.71e-103	319
k141_126688_63	SARG|gb|MBW0764195.1|ARO:3007027|salC	31.1	515	534	541	2.59e-53	188
k141_126688_63	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.2	535	534	655	1.65e-45	168
k141_126688_63	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.7	533	534	655	1.65e-45	168
k141_126688_63	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.0	535	534	655	4.22e-45	167
k141_126688_63	megares|MEG_7256|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|TLRC_1	28.1	526	534	540	2.20e-43	160
k141_126688_63	SARG|FR772051.1.gene9.p01	32.5	385	534	524	3.43e-37	143
k141_126688_63	SARG|gb|QNR09092.1|ARO:3007042|msr(G)	28.6	531	534	485	3.85e-37	142
k141_126688_63	SARG|gb|WP_096809342.1|ARO:3007029|salE	25.8	507	534	543	9.42e-36	139
k141_126688_63	NCBI|WP_063856937.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	29.7	407	534	522	4.11e-34	134
k141_126688_90	SARG|gi|857775939|emb|CRL64640.1|	25.1	235	329	392	9.66e-06	45.8
k141_126688_106	SARG|gb|AAC75271.1|ARO:3003952|yojI	29.5	207	339	547	5.56e-14	71.6
k141_126688_106	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.4	197	339	655	6.35e-11	62.4
k141_126688_106	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.4	197	339	655	6.35e-11	62.4
k141_126688_106	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.2	225	339	655	6.35e-11	62.4
k141_126688_106	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.4	197	339	655	6.35e-11	62.4
k141_126688_106	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.4	197	339	655	6.35e-11	62.4
k141_126688_106	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.4	197	339	655	6.35e-11	62.4
k141_126688_106	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.4	197	339	655	6.35e-11	62.4
k141_126688_106	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.4	197	339	655	6.35e-11	62.4
k141_126688_106	SARG|gb|AKA86814|ARO:3003746|optrA	28.4	197	339	655	6.35e-11	62.4
k141_126688_136	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	35.3	156	156	159	4.76e-28	100
k141_243712_10	SARG|L42544.gene.p01	26.7	442	600	651	7.97e-30	123
k141_243712_10	SARG|AAV80410	29.7	337	600	651	2.54e-29	122
k141_243712_10	SARG|ABB70054	28.0	446	600	639	7.69e-29	120
k141_243712_10	SARG|YP_002738300	28.0	446	600	639	7.69e-29	120
k141_243712_10	SARG|ABI81214	27.9	445	600	639	1.37e-28	119
k141_243712_10	SARG|BAB71968	27.8	446	600	639	1.83e-28	119
k141_243712_10	SARG|AJ514254.gene.p01	29.4	327	600	640	1.84e-28	119
k141_243712_10	SARG|X04388.gene.p01	27.8	446	600	639	2.44e-28	119
k141_243712_10	SARG|CAL69903	27.1	446	600	639	3.26e-28	118
k141_243712_10	SARG|CAV31157	27.6	446	600	639	5.80e-28	117
k141_243712_24	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	31.5	213	317	346	1.18e-19	87.0
k141_243712_56	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	24.6	688	635	703	1.36e-37	147
k141_142850_16	ResF|mre(A)_1_U92073_1	35.7	286	307	310	2.28e-49	165
k141_142850_16	SARG|gb|AAB64408.1|ARO:3007050|mreA	35.7	286	307	311	2.34e-49	165
k141_88991_30	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	27.8	619	622	633	6.96e-61	213
k141_88991_30	SARG|gb|AQX82857.1|ARO:3004185|mecD	26.9	565	622	678	3.82e-35	140
k141_88991_30	megares|MEG_3799|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	24.3	563	622	664	1.21e-33	135
k141_88991_30	megares|MEG_3800|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	23.9	561	622	665	2.91e-33	134
k141_88991_30	NCBI|WP_069996660.1|1|1|mecC3|mecC3|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC3|AMR|beta-lactam	23.8	560	622	665	3.90e-33	134
k141_88991_30	SARG|gb|CCC86795.1|ARO:3001209|mecC	24.0	563	622	665	7.00e-33	133
k141_88991_30	SARG|gi|446643958|ref|WP_000721304.1|	23.9	547	622	668	1.70e-32	132
k141_88991_30	NCBI|WP_128268231.1|1|1|mecC2|mecC2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC2|AMR|beta-lactam	23.9	561	622	665	2.25e-32	131
k141_88991_30	SARG|gi|686149587|ref|WP_031783560.1|	23.4	547	622	668	4.08e-32	130
k141_88991_30	SARG|gi|686291256|ref|WP_031861724.1|	23.7	536	622	668	4.08e-32	130
k141_88991_36	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.9	537	657	655	3.37e-101	322
k141_88991_36	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.9	537	657	655	4.72e-101	321
k141_88991_36	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.9	537	657	655	9.29e-101	320
k141_88991_36	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.9	537	657	655	1.30e-100	320
k141_88991_36	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.9	537	657	655	1.30e-100	320
k141_88991_36	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.9	537	657	655	1.30e-100	320
k141_88991_36	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.9	537	657	655	1.30e-100	320
k141_88991_36	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.9	537	657	655	1.30e-100	320
k141_88991_36	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.9	537	657	655	1.30e-100	320
k141_88991_36	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	35.8	537	657	655	1.83e-100	320
k141_88991_40	CARD|gb|AAC75429.1|ARO:3000833|evgS	25.3	403	775	1197	6.02e-36	145
k141_88991_40	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	28.6	227	775	359	3.24e-21	95.1
k141_88991_40	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	26.2	248	775	364	1.67e-18	87.0
k141_88991_40	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	26.2	248	775	364	1.67e-18	87.0
k141_88991_40	CARD|gb|AEX49906.1|ARO:3003583|basS	24.9	289	775	477	6.06e-14	73.9
k141_88991_44	CARD|gb|AAK37618.1|ARO:3005008|TxR	36.3	306	475	318	2.23e-61	202
k141_88991_44	CARD|gb|AAD51348.1|ARO:3003066|smeR	31.0	116	475	229	1.18e-10	60.5
k141_88991_52	NCBI|CCA59315.1|1|1|helR|helR||1|rifamycin|rifamycin|RNA_polymerase_recycling_motor_ATPase_HelR|AMR|rifamycin	31.3	195	515	722	1.76e-18	87.8
